age
Item
patients of more than 18 years of age
boolean
C0001779 (UMLS CUI [1])
Chemotherapy | Anemia | Hematologic Neoplasms
Item
patients presenting with anemia following chemotherapy
boolean
C3665472 (UMLS CUI [1])
C0002871 (UMLS CUI [2])
Solid tumour | Chemotherapy | Hematologic Neoplasms
Item
patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy
boolean
C0280100 (UMLS CUI [1])
C3665472 (UMLS CUI [2])
C0376545 (UMLS CUI [3])
patient inclusion regardless of chemotherapy
Item
- the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)
boolean
Eligibility Determination; Epoetin Alfa
Item
patients eligible for epoetin alfa biosimilar treatment
boolean
C0013893 (UMLS CUI [1,1])
C0357126 (UMLS CUI [1,2])
Chemotherapy
Item
patients are not receiving chemotherapy
boolean
C3665472 (UMLS CUI [1])
clinical trial participant (history); epoetin zeta
Item
patients already included in an epoetin zeta trial
boolean
C2242969 (UMLS CUI [1,1])
C1997870 (UMLS CUI [1,2])
Contraindication; epoetin zeta
Item
patients presenting with a contraindication to epoetin zeta
boolean
C0522473 (UMLS CUI [1,1])
C1997870 (UMLS CUI [1,2])
Hypersensitivity; Erythropoietin
Item
patients presenting with hypersensitivity to the active principle or any of the excipients
boolean
C0020517 (UMLS CUI [1,1])
C0014822 (UMLS CUI [1,2])
Decreased erythroid precursor production | Acquired red cell aplasia
Item
patient with erythroblastopenia or acquired pure red cell aplasia (aprca)
boolean
C0877221 (UMLS CUI [1])
C0340961 (UMLS CUI [2])
Uncontrolled hypertension
Item
patient with uncontrollable arterial hypertension
boolean
C1868885 (UMLS CUI [1])
Contraindication; Antithrombotic Agents
Item
patients who cannot receive adequate prophylaxis by antithrombotic agents
boolean
C0522473 (UMLS CUI [1,1])
C1704311 (UMLS CUI [1,2])